Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Published on March 3, 2026.
Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing Pharmaceutical Group, will grant Sanofi an exclusive worldwide license to develop, manufacture and commercialise rovadicitinib, receiving an upfront payment of $135 million. The company is also eligible for potential development, regulatory and sales milestones of up to $1.40 billion. The deal is subject to various closing conditions.
Related Articles
Florida bill to expand vaccine exemptions for schoolkids heads to Senate floor
A bill to expand vaccine exemptions for public K-12 schools in Florida is advancing despite opposition from Republicans and parents, sparking debate over vaccine safety and vaccine safety.
Why AI startups are selling the same equity at two different prices
As competition among AI startups increases, founders and VCs are increasingly using multi-tier valuation strategies to create market dominance and attract talent and investment, posing risks.
Pastor's voice lost from rare disease, restored with FDA-approved treatment
The FDA approved Papzimeos, a new treatment for respiratory papillomatosis, restoring the voice of impacted individuals like Pastor Lorenzo Small who experienced despair.